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SpainA multicentre, cross-sectional epidemiological survey was conducted to describe the health status of patients
with type 1 Gaucher disease (GD1) in Spain. Patient data were collected retrospectively from clinical records.
Therapeutic goals for seven clinical parameters were chosen as primary outcome measures. 108 GD1 patients
(mean age 44.8 years; 53% male) were recruited from 28 hospitals. Ninety-ﬁve patients (88%) were receiving
treatment for GD1. Hemoglobin concentration was the therapeutic goal with the highest level of achievement,
being met by 105 of 108 patients (97%), followed by the goals for liver volume (86/98 patients; 88%), spleen vol-
ume (67/77 patients; 87%) and platelet count (81/108 patients; 75%). The goal for bone mineral density (BMD)
wasmet by 48 of 75 patients (64%), and the goal for quality of lifewasmet by 65 of 103 patients (63%). Bone pain
was the parameter with the lowest level of achievement (goal met by 50/94 patients; 53%). The clinical informa-
tion most oftenmissing from patient records was the BMD Z-score (missing for 31% of patients). These data sug-
gest thatmost Spanish GD1 patients have good control over hematological and visceral parameters, but there is a
need to improve monitoring and treatment of GD-related bone disease.
© 2016 Shire and the Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Gaucher disease (GD; OMIM #230800) is an autosomal recessive
disorder caused by deﬁcient activity of the glucocerebrosidase enzyme
(GBA; EC 3.2.1.45) required for the degradation of glycosphingolipids.
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lsevier Inc. This is an open access artilysosomes of monocyte-lineage cells which develop into pathologic
“Gaucher cells” in visceral tissues [1,2]. GD has been classiﬁed into
three subtypes according to the presence or absence of neurological fea-
tures. Type 1 Gaucher disease (GD1) is themost common, and is charac-
terized by the lack of central nervous system involvement. GD2andGD3
are characterized by acute and chronic neurologic symptoms, respec-
tively. More than 350 mutations have been described in the GBA gene
region as the cause of GD [3]. The most common GBA genotype in GD1
patients is N370S/N370S, which tends to result in milder disease,
followed by N370S/L444P [4–6].
The prevalence of GD in the Iberian Peninsula is estimated to be
1:149,000, similar to that of other European populations [7]. Approxi-
mately 88% of the affected population haveGD1,with themost common
GBAmutations being N370S/L444P (32%) and N370S/N370S (17%). The
Spanish Foundation for the Study and Treatment of Gaucher Disease
(FEETEG) reports that there are currently 342 GD1 patients in Spain [8].
Clinical manifestations of GD1 commonly include anemia, thrombo-
cytopenia, hepatomegaly, splenomegaly and bone disease [9–12].cle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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abnormalities and secondary neurologic disease are also observed
[13–15].
There are currently two main types of treatment for GD1: enzyme
replacement therapy (ERT) and substrate reduction therapy (SRT),
which have both been shown to be effective in improving key disease
parameters [16].
The clinical heterogeneity of GD1 requires an individualized ap-
proach to disease management. In 2004, an international consensus
on the therapeutic goals for GD1 treatmentwas published to aid in ther-
apeutic decision-making [17]. The primary objective of the present
study was to describe the clinical characteristics and current health sta-
tus of GD1 patients managed in Spanish hospitals, particularly with re-
gard to the achievement of therapeutic goals. The secondary objectives
of the study included describing patients according to differences in
their disease management, such as by treatment and splenectomy
status.
2. Materials and methods
2.1. Study design and patients
This was a multicenter observational, cross-sectional epidemiologi-
cal study designed and conducted by investigators managing GD1 pa-
tients in Spanish hospitals (Study identiﬁcation number: SHI-TSE-
2011-01, Vall d'Hebron University Hospital). The study protocol was
reviewed and approved by ethics committees of the participating hospi-
tals, and was conducted in accordance with the Helsinki Declaration of
1975 as revised in 2008. All patients were required to sign an informed
consent form. Patients younger than 18 years of age provided informed
consent via a parent or legal representative.
The study recruitment period lasted 7months (June 2012 to January
2013) and data were gathered in a central database until April 2013. In-
volvement in the study was proposed to investigators by the study
sponsor if they were identiﬁed as managing GD1 patients in Spanish
hospitals or specialized centers. GD1 patients attending a routine clini-
cal visit during the study recruitment periodwere invited to participate.
Patientswhoagreed to participate and signed the consent formwere in-
cluded in the study. Patients were excluded if they were considered by
the investigator to have limited cognitive abilities or impaired capacity
to complete the study documentation.
The therapeutic goalsMAP (Monitor, Action and Progress) Tool®, an
application designed to collect and collate clinical data in one simple
visual output, was used for data collection. Data were collected retro-
spectively from the clinical records of participating patients during a
single study visit. These data included information recorded in the 6 to
12 months prior to the study visit, with the exception of the quality of
life (QoL) questionnaire that was supplied at the study visit.
2.2. Outcome measures
The therapeutic goals based on a published concensus [17] for seven
clinical parameters were the primary outcome measures for the study.
One measurement per parameter was collected for each patient
where available. The therapeutic goals for each parameter were deﬁned
as: 1) hemoglobin concentration ≥ 12 g/dL for men or ≥11 g/dL for
women and children b18 years old; 2) platelet count ≥120 × 109/L;
3) spleen volume ≤ 8multiples of normal (MN) asmeasured bymagnet-
ic resonance imaging (MRI) or ultrasound; 4) liver volume ≤ 1.5 MN as
measured by ultrasound; 5) bone pain ≤1 as a patient-reported level of
pain in the last 24 h according to the visual analog scale (VAS; 0–10)
where 0–1 is little or no pain, 2–4 is mild, 5–7 is moderate, and 8–10
is severe or extreme pain; 6) bone mineral density (BMD) Z-
score ≥ −1, measured by dual energy X-ray absorptiometry (DXA),
with the ability to distinguish where the scan was performed (in
the lumbar spine, femoral neck or distal forearm); 7) QoL SF-36score ≥ 70, obtained from the physical component of the SF-36 ques-
tionnaire [18] by averaging the scores for vitality and physical function
(scored from 0 to 100).
Additional information collected included sociodemographic and
physical characteristics, aswell as clinical data. Data collected from clin-
ical records included details of GD1 disease history, disease features, and
treatment.
2.3. Statistical analysis
Patient characteristics were summarized for the whole study popu-
lation, and also analyzed according to treatment status (on treatment
vs. untreated) and splenectomy status (splenectomized vs. non-
splenectomized). Primary clinical parameters were analyzed in groups
according to treatment status, splenectomy status, time since diagnosis
(b10 years vs. 10–20 years vs. N20 years), or time since treatment initi-
ation (b10 years vs. ≥10 years). A focused analysis of BMDwas also con-
ducted, classifying patients according to their BMD age-, sex- and race-
matched DXA Z-scores (retrieved from patients' medical records).
As this was a cross-sectional study and some data were missing for
the primary parameters, two independent analysis populations were
deﬁned for sensitivity analysis: the Full Analysis Set comprising all en-
rolled patients who met the enrolment criteria and gave informed con-
sent (n=108), and the Complete Data Analysis Set comprising patients
in the Full Analysis Set with complete data for all seven primary param-
eters (n=65). No imputationwas performed formissing values and in-
stances of missing data are indicated in the results tables.
Categorical variables were summarized by calculating the patient
frequencies and percentages. Comparisons of categorical variables be-
tween two or more groups were made through Fisher's exact and Chi-
square tests, respectively. Continuous variables were descriptively sum-
marized with means, standard deviations, medians and interquartile
ranges (IQRs). Comparison of continuous variables between two groups
was made using the Mann–Whitney U test or Student's t-test, and be-
tween three or more groups using the Kruskal-Wallis test. The two-
sided signiﬁcance level for all statistical tests was 0.05.
All statistical analyses were performed using the SAS software ver-
sion 9.2 (SAS Institute Inc., Cary, NC, USA).
3. Results
3.1. Study population
Approximately 50 investigators at 50 hospitals were invited to be in-
volved in the study; 35 investigators at 28 hospitals accepted, and re-
cruited patients into the study. One hundred and eight GD1 patients
geographically representing 10 of Spain's 17 autonomous communities
were enrolled (Fig. 1).
3.2. Patient characteristics
Patients had a mean age of 44.8 ± 16.6 years, and nine (8%) were
children (5–17 years of age). Fifty-seven patients (53%) were male
(Table 1). The most frequent GBA mutation was N370S, seen in 95 of
105 patients (90%). The median age of onset of GD1 symptoms was
20.7 (IQR 8.2–33.0) years, with diagnosis occurring at a median age of
28.0 (IQR 14.2–38.0) years. Pre-existing bone complications were re-
corded for 23 patients (21%).
Ninety-ﬁve patients (88%) were receiving treatment for GD1, of
whom 68 (72%) were receiving ERT (46 on imiglucerase, 22 on
velaglucerase alfa) and 20 (21%) were receiving SRT (miglustat). At
the study visit, the mean time on treatment for all patients was
10 years (119.0 ± 73.4 months; data not shown). Adverse events
were identiﬁed in the clinical records of three patients: impotence, mi-
graine and facial erythema, and pain during infusion. The latter was an
infusion-related reaction and was the only adverse event considered
Fig. 1.Geographic distribution of GD1 study patients. One hundred and eight patients from 28 hospitals across 10 of Spain's 17 autonomous communities were recruited to the study. The
dark gray circles on themap display the number of patients recruited from each community. The study population represents approximately a third of all GD1 patients in Spain, currently
reported to be 342 by the Spanish Foundation for the Study and Treatment of Gaucher Disease (FEETEG).
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itive test results for anti-drug antibodies. Patients on treatment had a
younger median age at diagnosis compared with untreated patients
(25.2 [IQR 12.2–34.2] years vs. 37.2 [IQR 31.5–49.1 years; p = 0.007]
and showed less bleeding tendency (6% vs. 23%; p = 0.040) (Table 1).
Twenty-seven patients (25%) had undergone splenectomy. Splenec-
tomized patients had an older mean age at study visit compared with
non-splenectomized patients (50.9 ± 13.8 years vs. 42.7 ± 17.1 years;
p = 0.0262), and were less likely to have a family history of GD1 (22%
vs. 49%; p = 0.0134) (Table 1); they also showed more comorbidities
(67% vs. 30%; p = 0.0006) and a higher percentage of osteonecrosis
(30% vs. 12%; p = 0.037).3.3. Achievement of therapeutic goals
3.3.1. Full analysis set
Therapeutic goals for the seven parameters were met by the major-
ity of patients (Table 2). Hemoglobin concentrationwas the therapeutic
goal with the highest level of achievement, beingmet by 105 of 108 pa-
tients (97%), followed by the goals for liver volume (86/98 patients;
88%), spleen volume (67/77 patients; 87%) and platelet count (81/108
patients; 75%). Bone pain in the past 24 h was the parameter with the
lowest level of goal achievement, with the goal being met by 50 of 94
patients (53%).
Median platelet count was higher for patients on treatment com-
pared with untreated patients (Table 2). Patients on treatment also
showed a lower median CCL18 level and chitotriosidase activity.
No statistically signiﬁcant differences were observed for therapeutic
goal achievement when splenectomized patients were compared with
non-splenectomized patients. However, splenectomized patients had
a signiﬁcantly higher mean platelet count and higher median CCL18
level (Table 2).Analyses according to time since diagnosis or treatment initiation
showed that patients whose diagnosis occurred 10 to 20 years ago
were more likely to have smaller values for liver volume compared
with those diagnosed more than 20 years ago, or less than 10 years
ago (1.1 ± 0.3 MN vs. 1.1 ± 0.2 MN vs. 1.4 ± 0.4 MN; p = 0.005).
Mean liver volume was also smaller for patients who started treatment
10 or more years ago, compared with those who started treatment less
than 10 years ago (1.1± 0.3MN vs. 1.2± 0.3MN; p=0.010), although
no statistically signiﬁcant differences were seen in the percentages of
patients meeting the therapeutic goal for liver volume (89.7% for
≥10 years vs. 88.6% for b10 years).
3.3.2. Complete data analysis set
We analyzed patients who had complete data for all seven primary
outcome measures (n = 65). The parameters with the most missing
values were BMD (missing data for 33 patients; 31%) and bone pain
(missing for 14 patients; 13%) (Table 2).
The mean values for each of the primary parameters for the Com-
plete Data Analysis Set were displayed on theMAP Tool® chart for a vi-
sual indication of this group's health status (Fig. 2). Analysis of the
Complete Data Analysis Set did not reveal notable differences in the ob-
served values for the primary parameters, nor in the percentages of pa-
tients achieving the therapeutic goals when compared with the Full
Analysis Set (Table 3). The therapeutic goals met by the lowest percent-
age of patients in the Complete Data Analysis Set were those related to
bone disease (Fig. 3).
3.3.3. Assessment of bone mineral density
Of the patients in the Full Analysis Set with available BMD data, 48
(48/75; 64%) had Z-scores in the normal range and 27 (36%) were
categorized as osteopenic or osteoporotic (Table 4). There was little dif-
ference between the treated and untreated patient groups in the per-
centages of patients with missing BMD data (29/95; 30.5% vs. 4/13;
Table 1
Patient characteristics of the Full Analysis Set (n = 108).
All patients By treatment status By splenectomy status
Untreated On treatment p-value Non
splenectomized
Splenectomized p-value
n = 108 n = 13 n = 95 n = 81 n = 27
Age (years) n (missing) 107 (1) 13 (0) 94 (1) 80 (1) 27 (0)
Mean (SD) 44.8 (16.6) 48.7 (19.8) 44.3 (16.2) nsT 42.7 (17.1) 50.9 (13.8) 0.0262T
Gender Male n (%) 57 (53) 9 (69) 48 (51) nsC 41 (51) 16 (59) nsC
Female n (%) 51 (47) 4 (31) 47 (50) 40 (49) 11 (41)
Height (m) n (missing) 96 (12) 11 (2) 85 (10) 71 (10) 25 (2)
Median (IQR) 1.7 (1.6–1.7) 1.7 (1.6–1.7) 1.7 (1.6–1.7) nsU 1.7 (1.6–1.7) 1.7 (1.6–1.7) nsU
Weight (kg) n (missing) 103 (5) 11 (2) 92 (3) 76 (5) 27 (0)
Median (IQR) 67 (58–75) 70 (55–76) 67 (58–75) nsU 66 (55–75) 70 (61–74) nsU
BMIa Underweight (b18.5) n (%) 3 (3) 1 (9) 2 (2) 3 (4) 0 (0)
Normal (18.5–24.99) n (%) 64 (67) 5 (46) 59 (70) 48 (69) 16 (64)
Overweight (≥25.0) n (%) 22 (23) 5 (46) 17 (20) nsF 15 (21) 7 (28) nsF
Obese (≥30.0) n (%) 6 (6) 0 (0) 6 (7) 4 (6) 2 (8)
Missing n 13 2 11 11 2
Age at symptom onset
(years)
n (missing) 88 (20) 7 (6) 81 (14) 61 (20) 27(0)
Median (IQR) 20.7 (8.2–33.0) 32.0 (10.0–39.0) 20.0 (8.0–33.0) nsU 22.7
(6.3-33.9)
18.6
(9.0–32.0)
nsU
Age at diagnosis (years) n (missing) 105 (3) 12 (1) 93 (2) 78 (3) 27 (0)
Mean (SD) 27.5 (16.4) 39.7 (14.7) 25.9 (16.0) 27.8 (16.5) 26.6 (16.3) nsT
Median (IQR) 28.0 (14.2–38.0) 37.2 (31.5–49.1) 25.2 (12.2–34.2) 0.007U 28.2
(14.2-38.0)
24.0
(12.2–38.0)
Family history of
Gaucher diseaseb
Yes n (%) 46 (43) 7 (54) 39 (41) nsC 40 (49) 6 (22) 0.0134C
Pre-existing bone
complication
Yes n (%) 23 (21) 3 (23) 20 (21) nsF 16 (20) 7 (26) nsC
Osteonecrosis Yes n (%) 18 (17) 2 (15) 16 (17) nsF 10 (12) 8 (30) 0.037C
Comorbidities Yes n (%) 42 (39) 4 (31) 38 (40) nsC 24 (30) 18 (67) 0.0006C
Transfusion dependency Yes n (%) 1 (1) 0 (0) 1 (1) nsF 0 (0) 1 (4)
Bleeding tendency Yes n (%) 9 (8) 3 (23) 6 (6) 0.040C 7 (9) 2 (7) nsF
Pulmonary involvement Yes n (%) 3 (3) 2 (15) 1 (1) 0.0377F 2 (3) 1 (4) nsF
Neurological symptoms Yes n (%) 3 (3) 0 (0) 3 (3) nsF 3 (4) 0 (0) nsF
Splenectomy Yes n (%) 27 (25) 2 (15) 25 (26) nsF 0 (0) 27 (100) NA
Genotype N370S/N370S n (%) 29 (27) 4 (33) 25 (27) 24 (31) 5 (19)
N370S/L444P n (%) 36 (33) 2 (17) 34 (37) 27 (35) 9 (33)
N370S/RECNCI1 n (%) 1 (1) 0 (0) 1 (1) 1 (1) 0 (0)
N370S/Other n (%) 29 (27) 2 (17) 27 (29) 17 (22) 12 (44)
L444P/Other n (%) 1 (1) 0 (0) 1 (1) 0.0472F 0 (0) 1 (4) nsF
D409H/D409Hc n (%) 1 (1) 0 (0) 1 (1) 1 (1) 0 (0)
D409H/Other n (%) 5 (5) 2 (17) 3 (3) 5 (6) 0 (0)
Other/Other n (%) 3 (3) 2 (17) 1 (1) 3 (4) 0 (0)
Missing n 3 1 2 3 0
Treatment Yes n (%) 95 (88) NA 95 (100) 70 (86) 25 (93) nsF
Type of treatment Imiglucerase n (%) 46 (43) – 46 (48) 35 (50) 11 (44)
Velaglucerase alfa n (%) 22 (20) – 22 (23) 15 (21) 7 (28)
Alglucerase n (%) 0 (0) – 0 (0) 0 (0) 0 (0)
Miglustat n (%) 20 (19) – 20 (21) 14 (20) 6 (24)
Imiglucerase +
miglustat
n (%) 3 (3) – 3 (3) 3 (4) 0 (0)
Other n (%) 4 (4) – 4 (4) 3 (4) 1 (4)
Adverse events Yes n (%) 3 (3) NA 3 (3) NA 3 (4) 0 (0) nsF
Infusion related reactions Yes n (%) 1 (1) NA 1 (1) NA 1 (1) 0 (0) nsF
FFisher's exact test.
CChi-square test.
TStudent's t-test.
UMann–Whitney U test.
SD, standard deviation; IQR, interquartile range; ns, non-signiﬁcant; NA, not applicable.
a Adultswere classiﬁed according to theWHOGlobal Database on BMI classiﬁcations [25] as deﬁned in the table. For children b18 years old, percentiles for BMIwere calculated according
to age and sex, and classiﬁed according to Underweight (b15th percentile), Normal (15–85th percentile), Overweight (N85–97th percentile) and Obese (N97th percentile).
b No information on the number of siblings in the study population is available as data were collected anonymously.
c Patient reclassiﬁed after ﬁnalization of the study as having GD type 3c due to clinical evolution of their disease.
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similar for the Complete Data Analysis Set.
In the Full Analysis Set, a higher percentage of splenectomized pa-
tients was categorized as osteoporotic (5 of 17 patients; 29%) compared
with non-splenectomized patients (3 of 58 patients; 5%). Furthermore, a
higher percentage of splenectomized patients had low BMD Z-scores
b−1 even if they were on treatment, though the number of untreated
patients was too small to draw any conclusions (Table 4).4. Discussion
We conducted a cross-sectional observational study to assess the
clinical characteristics and health status of Spanish GD1 patients. This
is the ﬁrst study where therapeutic goals have been used to evaluate
the health status of GD1 patients in Spain. Although GD1 is a rare dis-
ease, 108 patients participated in the study, accounting for approxi-
mately one third of all GD1 patients included in the Spanish GD
Table 2
Status and achievement of therapeutic goals in the Full Analysis Set (n = 108).
All patients By treatment status By splenectomy status
Untreated On treatment p-value Non-splenectomized Splenectomized p-value
n = 108 n = 13 n=95 n=81 n=27
Hemoglobin concentration (g/dL) n (missing) 108 (0) 13 (0) 95 (0) 81 (0) 27 (0)
Mean (SD) 13.6 (1.5) 13.3 (1.3) 13.6 (1.5) 0.459T 13.6 (1.5) 13.5 (1.3)
Median (IQR) 13.6 (12.8–14.6) 13.1 (12.8–14.3) 13.6 (12.8–14.6) 13.6 (12.9–14.6) 13.5 (12.5–14.5) 0.586U
Goal achievers
(♂≥12 and ♀≥11)
n (%) 105 (97) 79 (98) 26 (96) 1.000F
Platelet count (109/L) n (missing) 108 (0) 13 (0) 95 (0) 81 (0) 27 (0)
Mean (SD) 177 (89.1) 134 (57.3) 183 (91.2) 148 (50.1) 264 (120.0) b0.001T
Median (IQR) 164 (117–200) 135 (87–150) 167 (120–201) 0.048U 144 (110–186) 247 (170–351)
Goal achievers
(Platelet count ≥120)
n (%) 81 (75) 57 (70) 24 (89) 0.054C
Splenomegaly (MN) n (missing) 77 (4) 11 (0) 66 (4) 77 (4) 27 (0)
Median (IQR) 1.3 (1.0–4.0) 1.3 (1.0–5.0) 1.4 (1.0–4.0) 0.965U 1.3 (1.0–4.0) - NA
Goal achievers
(Spleen volume ≤8 MN)
n (%) 67 (87) 67 (87) - NA
Hepatomegaly (MN) n (missing) 98 (10) 13 (0) 85 (10) 75 (6) 23 (4)
Median (IQR) 1.0 (1.0–1.3) 1.1 (1.0–1.7) 1.0 (1.0–1.3) 0.192U 1.0 (1.0–1.2) 1.0 (1.0–1.5) 0.3225U
Goal achievers
(Liver volume ≤1.5 MN)
n (%) 86 (88) 67 (89) 19 (83) 0.468F
Bone pain in the last 24 hours
(VAS 0–10)
n (missing) 94 (14) 13 (0) 81 (14) 71 (10) 23 (4)
Median (IQR) 1.0 (0.0–3.0) 1.5 (0.0–2.0) 1.0 (0.0–3.0) 0.813U 1.0 (0.0–3.0) 2.0 (0.0–3.0) 0.365U
Goal achievers
(VAS ≤1)
n (%) 50 (53) 41 (58) 9 (39) 0.120C
Bone pain among patients having
paina (VAS N0)
n (%) 59 (63) 8 (62) 51 (63) 43 (61) 16 (70)
Median (IQR) 2.0 (1.0- 4.0) 2.0 (1.8–6.5) 2.4 (1.0–4.0) 0.525U 2.0 (1.0–4.0) 3.0 (2.0–3.5) 0.643U
Bone mineral density (DXA
Z-score)
n (missing) 75 (33) 9 (4) 66 (29) 58 (23) 17 (10)
Mean (SD) -0.7 (1.3) -0.7 (1.6) -0.8 (1.2) 0.931T -0.6 (1.2) -1.1 (1.5) 0.157T
Goal achievers
(DXA Z-score ≥-1)
n (%) 48 (64) 39 (67) 9 (53) 0.28C
Physical Component Score of
SF-36 (0 - 100)
n (missing) 103 (5) 13 (0) 90 (5) 78 (3) 25 (2)
Median (IQR) 80 (60–85) 75 (63–80) 80 (60–85) 0.823U 80 (60–88) 75 (60–83) 0.684U
Goal achievers
(PCS ≥70)
n (%) 65 (63) 49 (63) 16 (64) 0.915C
CCL18 (ng/mL) n (%) 67 (62) 10 (77) 57 (60) 49 (61) 18 (67)
n (missing) 59 (8) 9 (1) 50 (7) 44 (5) 15 (3)
Median (IQR) 259 (136–543) 515 (310–967) 215 (131–448) 0.018U 215 (116–419) 631 (152–877) 0.034U
Chitotriosidase (nmol/mL/h) n (%) 88 (82) 12 (92) 76 (80) 65 (80) 23 (85)
n (missing) 81 (7) 12 (0) 69 (7) 59 (6) 22 (1)
Median (IQR) 1257 (553–3150) 2896 (164–-8491) 987 (456–2800) 0.002U 1143 (380–3150) 1729 (818–3505) 0.3529U
Number of goals achieved (0–7) n 108
Mean (SD) 4.6 (1.4)
Patients achieving goals
7 n (%) 10 (9)
6 n (%) 21 (19)
5 n (%) 33 (31)
4 n (%) 21 (19)
3 n (%) 11 (10)
2 n (%) 12 (11)
F, Fisher’s exact test; C, Chi-square test; T, Student’s t-test; U, Mann-Whitney U test.
SD, standard deviation; IQR, interquartile range; NA, not applicable.
a VAS pain value of patients who declared having any level of pain in the past 24 h.
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Gaucher community as an effective tool. Therefore, statistical analyses inde-
pendent from theMAP Tool®were conducted to analyze all data collected.
Our data share similarities with a previous report describing the distri-
bution, clinical and genetic characteristics of GD1 patients in the Iberian
Peninsula (Spain and Portugal) [7]. The age at diagnosis was comparable
(27.5 vs. 28.7 years), and splenectomywasmore common in older patients.
The genotypes reported were consistent with those found in our cohort,
with N370S being the most frequent GBA mutation. They also reported
GD1 patients with the D409H mutation, an allele that has been linked to
cardiovascular and neurological symptoms, and is seen inGD3; six GD1 pa-
tients in our study had the D409Hmutation, though only one patient was
homozygous for this allele. The D409H homozygous patient was
reclassiﬁed after the ﬁnalization of the study as having GD type 3c, due to
clinical evolution of their disease. This reclassiﬁcation does not compromise
the ﬁnal results of the study.Compared with other countries, our study population had a high
average age at diagnosis which has been reported to be 17 years
in Latin America [19] and 22 years in France [20] though these
studies included patients with all types of GD. The study in Latin
America reported a much lower percentage of splenectomized patients
compared with our study (7% vs. 25%), but a similar percentage of pa-
tients receiving treatment (89% vs. 88%). The study in France had a sim-
ilar number of splenectomized patients compared with our study (19%
vs. 25%), but a lower percentage of patients receiving treatment (78%
vs. 88%).
Nearly all patients in our study (N85%) were meeting the thera-
peutic goals for hemoglobin concentration, hepatomegaly and spleno-
megaly, and three-quarters of patients were meeting the goal for
platelet count.
Most patients (88%)were receiving ERT or SRT as treatment for GD1.
Patients on treatment had signiﬁcantly lower CCL18 levels and
Fig. 2. Graphical display of health status in the Complete Data Analysis Set. The mean observed values for primary parameters for the Complete Data Analysis Set are visualized using the
MAP Tool® chart. Values indicating better health status appear toward the outermost ring of the chart, while those indicating poorer health status are plotted toward the innermost ring.
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markers are markedly elevated in GD1 patients and are viewed as a re-
ﬂection of the overall body burden of Gaucher cells [21].
Three adverse events were found in the clinical records of our
study patients. One of these events was considered to be treatment-
related where the patient experienced diffuse abdominal pain during
and after intravenous infusion with velaglucerase alfa. The patient
discontinued treatment due to poor tolerance.
The most important ﬁnding of this study is evidence that patients are
not being followed appropriately for bone disease. Clinical or radiographic
evidence of bone disease is found in 70–100% of GD1 patients and ranges
from asymptomatic osteopenia to focal lytic or sclerotic lesions and
osteonecrosis [12]. Furthermore, bone disease commonly developswithout
obvious symptoms and although ERTmay be effective for skeletal patholo-
gy, the response can take longer than the time taken to ameliorate other
symptoms [22,23]. It is also possible for bone disease to develop during
treatment [20]. In our study, a third of patientswere not routinely followed
for BMD, and 36% of those who were followed had a Z-score in the
osteopenic or osteoporotic range. Low BMD of the lumbar spine has been
reported as a strong risk factor for fractures in GD1 patients [24]. We
found that splenectomy was associated with low BMD Z-scores b−2.5,
which is consistent with previous data suggesting that deterioration of
bone disease often occurs after splenectomy [13].
A limitation of our study is, as in every rare disease, the low number
of accessible patients and geographical dispersion, resulting in a low
power to detect differences and a decreased ability to generalize
due to potential selection bias. As this was an observational study
based on data collected from routine clinical practice, there was no ran-
domization, nor a sampling procedure to assure representativeness.
Furthermore, only one measurement per parameter was collected
from each patient. This may impact the study results since patients
had varying degrees of disease severity, and different lengths oftime on treatment and time since undergoing splenectomy. No adjust-
ments weremade for these factors whenmaking comparisons between
groups and the data reﬂect the heterogeneity observed in clinical
practice.
5. Conclusions
GD1 patients in Spain appear to have good control of hematologic
and visceral parameters and most patients are meeting the established
therapeutic goals [17] for these clinical parameters. Bone disease in
GD1 patients is not always followed up by physicians in Spain despite
its high prevalence. Monitoring and treatment of GD-related bone dis-
ease must be improved and further prospective studies are needed to
better assess the impact of treatment on bone parameters.
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Table 3
Status and achievement of therapeutic goals in the Complete Data Analysis Set (n = 65).
All patients By treatment status By splenectomy status
Untreated On treatment p-value Non-splenectomized Splenectomized p-value
n = 65 n = 9 n = 56 n = 50 n = 15
Hemoglobin concentration
(g/dL)
n 65 9 56 50 15
Mean (SD) 13.7 (1.3) 13.1 (1.4) 13.8 (1.2) 13.8 (1.3) 13.2 (1.1) nsT
Median (IQR) 13.6 (12.9–14.5) 13.1 (12.4–13.9) 13.6 (12.9–14.5) nsU 13.6 (13.0–14.6) 13.2 (12.5–14.2)
Goal achievers
(♂≥12 and ♀≥11)
n (%) 64 (99) 50 (100) 14 (93) nsF
Platelet count (109/L) n 65 9 56 50 15
Mean (SD) 162 (60.3) 108 (38.2) 171 (58.8) 0.003T 150 (51.1) 205 (70.8) 0.002T
Goal achievers
(Platelet count ≥120)
n (%) 48 (74) 35 (70) 13 (87) nsF
Splenomegaly (MN) n 50 8 42 50 15
Median (IQR) 1.2 (1.0–4.0) 2.8 (1.2–5.4) 1.1 (1.0–3.0) nsU 1.2 (1.0–4.0) – NA
Goal achievers
(Spleen volume ≤8 MN)
n (%) 45 (90) 45 (90) – NA
Hepatomegaly(MN) n 65 9 56 50 15
Median (IQR) 1.1 (1.0–1.5) 1.2 (1.1–2.0) 1.0 (1.0–1.5) nsU 1.0 (1.0–1.5) 1.5 (1.0–1.7) nsU
Goal achievers
(Liver volume ≤1.5 MN)
n (%) 55 (85) 44 (88) 11 (73) nsF
Bone pain in the last 24 hours
(VAS 0–10)
n 65 9 56 50 15
Median (IQR) 1.0 (0.0–2.5) 2.0 (1.5–7.0) 2.4 (1.0–4.1) nsU 1.0 (0.0–2.4) 1.0 (0.0–3.0) nsU
Goal achievers
(VAS ≤1)
n (%) 38 (59) 30 (60) 8 (53) nsC
Bone pain among patients
having pain
(VAS N0)
n (%) 37 (56.9) 6 (66.7) 31 (55.4) 28 (56.0) 9 (60.0)
Median (IQR) 2.0 (1.0–4.1) 2.0 (1.5–7.0) 2.4 (1.0–4.1) nsU 2.0 (1.0–5.0) 3.0 (2.0–3.0) nsU
Bone mineral density (DXA
Z-score)
n 65 9 56 50 15
Mean (SD) −0.8 (1.3) -0.7 (1.6) −0.8 (1.2) nsT −0.7 (1.2) −1.2 (1.5) nsT
Goal achievers
(DXA Z-score ≥-1)
n (%) 40 (62) 33 (66) 7 (47) nsC
Physical component score of
SF-36 (0–100)
n 65 9 56 50 15
Median (IQR) 80 (68–85) 75 (63–80) 81 (68–88) nsU 80 (63–85) 80 (68–85) nsU
Goal achievers
(PCS ≥70)
n (%) 46 (71) 36 (72) 10 (67) nsF
Number of goals achieved
(0–7)
n 65
Mean (SD) 5.2 (1.2)
Patients achieving goals
7 n (%) 10 (15)
6 n (%) 15 (23)
5 n (%) 24 (37)
4 n (%) 10 (15)
3 n (%) 4 (6)
2 n (%) 2 (3)
F, Fisher’s exact test; C, Chi-square test; T, Student’s t-test; U, Mann–Whitney U test.
SD, standard deviation; ns, non-signiﬁcant; NA, not applicable.
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